Leerink Partners Remains Bullish on Heron Therapeutics (HRTX) Following Announced Management Changes
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Leerink Partners reiterated an Outperform rating and $33.000 price target on Heron Therapeutics (NASDAQ: HRTX) following recently announced management departures. While the departures will likely grab investor attention, Leerink believes that the changes should not be interpreted as a sign of instability. CMO Neil Clendeninn, Senior VP and President of Technical Operations Paul Marshall, and CFO Brian Drazba. Mr. Clendeninn and Mr. Marshall’s resignations became effective 9/30.
Analyst Jason Gerberry commented, "We do not view the recently announced management departures as reason for concern. This evening we caught up with Heron CEO Barry Quart to discuss the recent mgmt departures announced Friday evening. We do not view the departures as reason for concern as (1) two of the departures were 'stop gap' hires, in our view, brought on to help the company through the Sustol CRL (complete response letter) process; (2) the CFO change is being made so the company can fill the role with more of an outward (investor) facing individual."
Shares of Heron Therapeutics closed at $17.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Heron Therapeutics (HRTX) Prices Offering at $12.20/Share
- Skyworks Solutions (SWKS) PT Raised to $105 at Oppenheimer Following 1Q Report
- UPDATE: Stifel Upgrades Abraxas Petroleum (AXAS) to Buy Amid Emerging Delaware Basin Potential
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!